Preview

Научно-практическая ревматология

Расширенный поиск

Европейский конгресс ревматологов, Рим (10–13 июня 2015 г.), – проблемы ревматоидного артрита

https://doi.org/10.14412/1995-4484-2015-661-670

Полный текст:

Аннотация

10–13 июня 2015 г. в Риме проходил ежегодный 16-й Европейский конгресс ревматологов, который, несомненно, является центральным событием мировой ревматологии. В его работе приняли участие около 14 тыс. делегатов: врачей, ученых, работников здравоохранения, пациентов, представляющих более чем 100 стран мира. Были рассмотрены 4300 тезисов, 82% из них отобраны для публикации. Программа конгресса была чрезвычайно многообразна, она включала обсуждение новых данных, касающихся диагностики и лечения наиболее распространенных ревматических заболеваний, проблем их этиологии и патогенеза, персонифицированной терапии и многое другое. Более подробно в данном сообщении представлены материалы, отражающие современные тенденции в лечении ревматоидного артрита.

Об авторах

А. С. Авдеева
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия


Л. Н. Денисов
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия


Е. Л. Насонов
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, Москва, Россия 119991 Москва, ул. Трубецкая, 8, стр. 2
Россия


Список литературы

1. Lu L, Choi HK, Schoenfeld SR, et al. Improved survival in rheumatoid arthritis: a general population-based study. Ann Rheum Dis. 2015;74(Suppl 2):137. doi: 10.1136/annrheumdis-2015-eular.3507

2. Ajeganova S, Hafströ m I, Svensson B, et al. Failure to achieve early remission augments risk of mortality in rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):140. doi: 10.1136/annrheumdis-2015-eular.5125

3. Svensson B, Schaufelberger C, Teleman A, Theander J. Remission and response to early treatment of RA assessed by the Disease Activity Score. Rheumatology (Oxford). 2000;39:1031–6. doi: 10.1093/rheumatology/39.9.1031

4. Svensson B, Boonen A, Albertsson K, et al.; for the BARFOT Study Group. Low-dose prednisolone in addition to the initial diseasemodifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum. 2005;52:3360–70. doi: 10.1002/art.21298

5. Ajeganova S, Svensson B, Hafströ m I, on behalf of the BARFOT Study Group. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow- up of a 2-year randomised trial. BMJ Open. 2014;4:e004259. doi: 10.1136/bmjopen-2013-004259

6. Emery P, Roy M, Fleischmann RM, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009; 60:2272–83. doi: 10.1002/art.24638

7. Emery R, Fleischmann R, Xu S,et al. Treatment target status at 6 months and long-term outcomes at 5 years: analysis of methotrexate-naive patients with rheumatoid arthritis in the GO-BEFORE trial. Ann Rheum Dis. 2015;74(Suppl 2):711. doi: 10.1136/annrheumdis-2015-eular.3647

8. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509. doi: 10.1136/annrheumdis-2013-204573

9. Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России –2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477–94 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(5):477–94 (In Russ.)]. doi: 10.14412/1995-4484-2014-477-494

10. Verschueren P, de Cock D, Corluy L, et al. Remission induction with DMARD combinations and glucocorticoids is not superior to remission induction with MTX monotherapy and glucocorticoids: week 52 results of the high-risk group from the CARERA trial. Ann Rheum Dis. 2015;74(Suppl 2):139. doi: 10.1136/annrheumdis-2015-eular.4018

11. Verschueren P, de Cock D, Corlue L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74:27–34. doi:10.1136/annrheumdis-2014-205489

12. Verschueren P, de Cock D, Corlue L, et al. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther. 2015:17:29. doi: 10.1186/s13075-015-0611-8

13. De Cock D, Corluy L, Joos R, et al. Low-risk patients also benefit from remission induction treatment in early rheumatoid arthritis: week 52 results from the CARERA trial. Ann Rheum Dis. 2015;74(Suppl 2):236. doi: 10.1136/annrheumdis-2015-eular.3984

14. Kuijper T, Luime J, de Jong P, et al. Tapering DMARDs in the TREACH trial – flare rates, sustained remission and radiological progression. Ann Rheum Dis. 2015;74(Suppl 2):76. doi: 10.1136/annrheumdis-2015-eular.5218

15. De Jong PH, Hazes JM, Barenndregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72:72–8. doi: 10.1136/annrheumdis-2011-201162

16. De Jong PH, Hazes JM, Han HK, et al. Randomized comparison of initial triple DMAR therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73:1331–9. doi: 10.1136/annrheumdis-2013-204788

17. Bijlsma JW, Welsing PM, Woodworth TG, et al. Rapid and sustained remission in early rheumatoid arthritis (RA) treated to target with tocilizumab, methotrexate, or their combination: the U-ACTEarly Strategy Study. Ann Rheum Dis. 2015;74(Suppl 2):77. doi: 10.1136/annrheumdis-2015-eular.2287

18. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2015-207628

19. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of remission: the role of acute phase reactants. Arthritis Rheum. 2011;62:43–52. doi: 10.1002/art.27740

20. Jorgensen TS, Tarp S, Furst DE, et al. Added-value of combining methotrexate with a biological agent compared to biological monotherapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2015;74(Suppl 2):239. doi: 10.1136/annrheumdis-2015-eular.3396

21. Emery P, Bingham CO, Burmester GR, et al. The first study of certolizumab pegol in combination with methotrexate in DMARD-naive early rheumatoid arthritis patients led to sustained clinical response and inhibition of radiographic progression at 52 weeks: the C-EARLY randomized, double-blind, controlled phase 3 study. Ann Rheum Dis. 2015;74(Suppl 2):712. doi: 10.1136/annrheumdis-2015-eular.1493

22. Emery P, Bingham CO, Burmester GR, et al. Improvements in patient-reported outcomes and workplace and household productivity following 52 weeks of treatment with certolizumab pegol in combination with methotrexate in DMARD-naive early rheumatoid arthritis patients: results from the C-EARLY randomized, double-blind, controlled phase 3 study. Ann Rheum Dis. 2015;74(Suppl 2):712. doi: 10.1136/annrheumdis-2015-eular.1499

23. Emery P, Burmester GR, Bykerk V, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b multicenter, randomized, active-controlled AVERT study of 24 months, with a 12 months, double-blind treatment period. Ann Rheum Dis. 2015;74:19–26. doi: 10.1136/annrheumdis-2014-206106

24. Burmester G, Furst DE, Combe BG, et al. Stringent criteria for low disease activity and remission after 12 month of treatment, and after treatment withdrawal, with abatacept monotherapy, abatacept with methotrexate or methotrexate alone in early rheumatoid arthritis. Arthritis Rheum. 2014;66(Suppl):2468 (abst).

25. Bykerk VP, Burmester GR, Combe BG, et al. On drug and drugfree remission by baseline disease duration in the AVERT trial: abatacept versus methotrexate comparison in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):477. doi: 10.1136/annrheumdis-2015-eular.2071

26. Mehta P, Davy K, Williamson R, et al. Meta-analysis of randomised controlled trials of biologics in DMARDS-naive and DMARDS-inadequate responder subjects with rheumatoid arthritis: efficacy and safety. Ann Rheum Dis. 2015;74(Suppl 2):239. doi: 10.1136/annrheumdis-2015-eular.2358

27. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015. doi: 10.1038/nrrheum.2015.8

28. Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, et al. Randomized trial of stopping tnf-inhibitors in rheumatoid arthritis patients with stable remission or low disease activity in the Netherlands. Ann Rheum Dis. 2015;74(Suppl 2):709. doi: 10.1136/annrheumdis-2015-eular.2388

29. Hernandez MV, Gomez-Puerta JA, Canete JD, et al. Biologic DMARDs in patients with rheumatoid arthritis on a Spanish registry: predictors of therapy discontinuation due to remission. Ann Rheum Dis. 2015;74(Suppl 2):464. doi: 10.1136/annrheumdis-2015-eular.2729

30. Desouches S, Avenel G, Kozyreff M, et al. Experience of spacing and withdrawal of biological agents in rheumatoid arthritis patients in remission: identification of relapse predictive factors. Ann Rheum Dis. 2015;74(Suppl 2):470. doi: 10.1136/annrheumdis-2015- eular.3533

31. Okano T, Inui K, Tada M, et al. Medication interval of adalimumab for rheumatoid arthritis patients might be extended after the achievement of low disease activity – KABUKI study. Ann Rheum Dis. 2015;74(Suppl 2):471. doi: 10.1136/annrheumdis-2015-eular.2609

32. Galloway JB, Kingsley G, Ma M, et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Ann Rheum Dis. 2015;74(Suppl 2):706. doi: 10.1136/annrheumdis-2015-eular.4684

33. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2014-206439

34. Haschka J, Englbrecht M, Hueber AJ, et al. RETRO – study of reduction of therapy in patients with rheumatoid arthritis in ongoing remission. Ann Rheum Dis. 2015;74(Suppl 2):668. doi: 10.1136/annrheumdis-2015-eular.5961

35. Espinosa F, Arce-Salinas CA, Alfaro-Lara R. Systematic review and meta-analysis on the efficacy of leflunomide vs. methotrexate as monotherapy in patients with rheumatoid arthritis (RA). Ann Rheum Dis. 2015;74(Suppl 2):739. doi: 10.1136/annrheumdis-2015-eular.3431

36. Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(прил. 1):64–76 [Nasonov EL. Methotrexate for rheumatoid arthritis – 2015: new facts and ideas. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(Suppl 1):64–76 (In Russ.)].

37. Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8–26 [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8–26]. doi: 10.14412/1995-4484-2014-8-26

38. Levitsky A, Erlandsson M, van Vollenhoven RF, et al. Serum survivin predicts treatment response in active rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):224. doi: 10.1136/annrheumdis-2015-eular.3151

39. Van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomized trial. Lancet. 2009;374:459–66. doi: 10.1016/S0140-6736(09)60944-2

40. Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379:1712–20. doi: 10.1016/S0140-6736(12)60027-0

41. Gu YJ, Jin SD, Wang F, et al. Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer. Biomed Pharmacother. 2014;68:471–5. doi: 10.1016/j.biopha.2014.03.010

42. Chun-Lai T, Murad S, Erlandsson MC, et al. Recognizing rheumatoid arthritis: oncoprotein survivin opens new possibilities: a population-based case-control study. Medicine (Baltimore). 2015;94:e468. doi: 10.1097/MD.0000000000000468

43. Cregan S, Creevey K, McGarry T, et al. The role of epigenetics in determining the clinical response to methotrexate for the treatment of rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):897. doi: 10.1136/annrheumdis-2015-eular.1825

44. Neumann E , Lefevre S, Zimmermann B, et al. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med. 2010;16:458–468. doi: 10.10.1016/j.molmed.2010.07.004

45. Cribbs AP, Kennedy A, Penn H, et al. Treg cell function in rheumatoid arthritis is compromised by CTLA-4 promoter methylation resulting in a failure to activate the indolamine 2,3-deoxygenase pathway. Arthritis Rheum. 2014; 66:2344–54. doi: 10.1002/art.38715

46. Cribbs AP, Kennedy A, Penn H, et al. Methotrexate restores regulatory T cell function through demethelation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. Arthritis Rheum. 2015;67:1182–92. doi: 10.1002/art.39031

47. Hollan I, Vuong TT, Reine TM, et al. Anti-rheumatic therapy reduces syndecan-1 shedding in rheumatoid arthritis (RA). Ann Rheum Dis. 2015;74(Suppl 2):1011. doi: 10.1136/annrheumdis-2015-eular.3266

48. Lee JJ, Bykerk VP, Dresser GK, et al. Does methotrexate lower serum uric acid levels? Data from the CATCH cohort. Ann Rheum Dis. 2015;74(Suppl 2):248. doi: 10.1136/annrheumdis-2015-eular.2595

49. Asai S, Takahashi N, Funahashi K, et al. Effects of concomitant methotrexate on the long-term outcome of knee joint destruction in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors. Ann Rheum Dis. 2015;74(Suppl 2):220. doi: 10.1136/annrheumdis-2015-eular.1337

50. Kawasaki T, Okumura N, Mimura T, et al. Hip joint protection and falling numbers of total hip arthroplasties in cases of rheumatoid arthritis: does medication work? Ann Rheum Dis. 2015;74(Suppl 2):1069. doi: 10.1136/annrheumdis-2015-eular.3712

51. Widdifield J, Moura C, Wang Y, et al. The influence of drug exposures on joint surgeries in rheumatoid arthritis patients: crossprovincial comparisons. Ann Rheum Dis. 2015;74(Suppl 2):72. doi: 10.1136/annrheumdis-2015-eular.4981

52. Dolan L, Joshi A. A true to life study on effects of switching from oral to subcutaneous methotrexate. Ann Rheum Dis. 2015;74(Suppl 2):1065. doi: 10.1136/annrheumdis-2015-eular.1058

53. Studenic P, Alasti F, Smolen JS, et al. Kidney function and effectiveness of methotrexate treatment in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(Suppl 2):453. doi: 10.1136/annrheumdis- 2015-eular.5293

54. Conigliaro P, Triggianese P, Sunzini F, et al. Treatment targets with first line biological agents in early and longstanding rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(Suppl 2):467. doi: 10.1136/annrheumdis-2015-eular.6397

55. Lamers-Karnebeek FBG, Jansen T, van Riel P, et al. Ultrasonography as predictor for flare in rheumatoid arthritis patients with low disease activity: nine month results from POETUS- study. Ann Rheum Dis. 2015;74(Suppl 2):140. doi: 10.1136/annrheumdis-2015-eular.5185

56. Avila MG, Alonso A, Lopez Lasanta M, et al. Long-term followup study of biological therapy discontinuation in rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):475. doi: 10.1136/annrheumdis-2015-eular.4078

57. Hattori Y, Kaneko A, Kida D, et al. Retention rate and discontinuation due to efficacy and safety in Japanese patients with rheumatoid arthritis receiving adalimumab therapy: a multicenter study. Ann Rheum Dis. 2015;74(Suppl 2):472. doi: 10.1136/annrheumdis- 2015-eular.1098

58. Jani M, Barton A, Warren R, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53:213–22. doi: 10.1093/rheumatology/ket260

59. Александрова ЕН, Насонов ЕЛ. Иммуногенность ингибиторов фактора некроза опухоли α при лечении ревматоидного артрита. Научно-практическая ревматология. 2012;53(прил. 4):22–7 [Aleksandrova EN, Nasonov EL. Immunogenicity inhibitors of tumor necrosis factor α in the treatment of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;53(Suppl 4):22–7 (In Russ.)].

60. Ruiz-Esquide V, Zufferey P, Yagü e J, et al. Relationship between clinical remission and serum levels of tocilizumab in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):77. doi: 10.1136/annrheumdis-2015-eular.3444

61. Hammer HB, Bolstad N, Warren DJ, et al. Patients with low serum adalimumab concentrations display poor ultrasonographic response to treatment; results of a follow-up study of patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):461. doi: 10.1136/annrheumdis-2015-eular.1328

62. Opris D, Borangiu A, Gudu T, et al. Does serum drug level correlates with ultrasound evaluation in patients with rheumatoid arthritis treated with TNF antagonists? Ann Rheum Dis. 2015;74(Suppl 2):702. doi: 10.1136/annrheumdis-2015-eular.2844

63. Paredes B, Plasencia C, Pascual-Salcedo D, et al. Influence of optimization of biological therapies on immunogenicity in a cohort of rheumatoid arthritis with low disease activity. Ann Rheum Dis. 2015;74(Suppl 2):458. doi: 10.1136/annrheumdis-2015-eular.5515

64. Denarie D, Rinaudo M, Thomas T, et al. Methotrexate reduced TNF bioactivity by anti-infliximab antibody prevention in rheumatoid arthritis patients treated with infliximab. Ann Rheum Dis. 2015;74(Suppl 2):459. doi: 10.1136/annrheumdis-2015-eular.3296

65. L’Ami M, Kneepkens E, Krieckaert C, et al. The effect of methotrexate in treatment with adalimumab and etanercept in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):708. doi: 10.1136/annrheumdis-2015-eular.2689

66. Gottenberg JE, Morel J, Ravaud P, et al. Tolerance of rituximab, abatacept and tocilizumab in common practice: analysis of the 3 registries of the French society of rheumatology (AIR, ORA AND REGATE). Ann Rheum Dis. 2015;74(Suppl 2):78. doi: 10.1136/annrheumdis-2015-eular.3807

67. Ozguler Y, Hatemi G, Ugurlu S, et al. Restarting biologics in patients who developed tuberculosis during anti TNF-alpha treatment. Ann Rheum Dis. 2015;74(Suppl 2):472. doi: 10.1136/annrheumdis-2015-eular.2512

68. Fang L, Liao Z, Lin Z, et al. Safety of adalimumab therapy in HbsAg carriers with rheumatoid arthritis: a prospective study. Ann Rheum Dis. 2015;74(Suppl 2):464. doi: 10.1136/annrheumdis-2015-eular.6487


Для цитирования:


Авдеева А.С., Денисов Л.Н., Насонов Е.Л. Европейский конгресс ревматологов, Рим (10–13 июня 2015 г.), – проблемы ревматоидного артрита. Научно-практическая ревматология. 2015;53(6):661-670. https://doi.org/10.14412/1995-4484-2015-661-670

For citation:


Avdeeva A.S., Denisov L.N., Nasonov E.L. THE EUROPEAN CONGRESS OF RHEUMATOLOGY, ROME (10–13 JUNE 2015): PROBLEMS OF RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2015;53(6):661-670. (In Russ.) https://doi.org/10.14412/1995-4484-2015-661-670

Просмотров: 291


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)